Health ❯ Medicine ❯ Clinical Trials ❯ Drug Development
Preclinical data showing that DKK1 inhibition revives checkpoint blockade efficacy against bone tumors have triggered clinical trials of DKN-01 guided by CHI3L3 biomarker research.